Literature DB >> 32803721

Curative gene therapies for rare diseases.

Rocio Maldonado1, Sami Jalil1, Kirmo Wartiovaara2,3.   

Abstract

Diseases caused by alterations in the DNA can be overcome by providing the cells or tissues with a functional copy of the mutated gene. The most common form of gene therapy implies adding an extra genetic unit into the cell. However, new genome engineering techniques also allow the modification or correction of the existing allele, providing new possibilities, especially for dominant diseases. Gene therapies have been tested for 30 years in thousands of clinical trials, but presently, we have only three authorised gene therapy products for the treatment of inherited diseases in European Union. Here, we describe the gene therapy alternatives already on the market in the European Union and expand the scope to some clinical trials. Additionally, we discuss the ethical and regulatory issues raised by the development of these new kinds of therapies.

Entities:  

Keywords:  CRISPR-Cas9; Gene therapy; Genetic engineering

Year:  2020        PMID: 32803721     DOI: 10.1007/s12687-020-00480-6

Source DB:  PubMed          Journal:  J Community Genet        ISSN: 1868-310X


  30 in total

1.  Mechanisms of haploinsufficiency revealed by genome-wide profiling in yeast.

Authors:  Adam M Deutschbauer; Daniel F Jaramillo; Michael Proctor; Jochen Kumm; Maureen E Hillenmeyer; Ronald W Davis; Corey Nislow; Guri Giaever
Journal:  Genetics       Date:  2005-02-16       Impact factor: 4.562

2.  Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics.

Authors:  Artur V Cideciyan; Tomas S Aleman; Sanford L Boye; Sharon B Schwartz; Shalesh Kaushal; Alejandro J Roman; Ji-Jing Pang; Alexander Sumaroka; Elizabeth A M Windsor; James M Wilson; Terence R Flotte; Gerald A Fishman; Elise Heon; Edwin M Stone; Barry J Byrne; Samuel G Jacobson; William W Hauswirth
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-22       Impact factor: 11.205

3.  'Bubble boy' gene therapy reignites commercial interest.

Authors:  Elie Dolgin
Journal:  Nat Biotechnol       Date:  2019-07       Impact factor: 54.908

Review 4.  Gene-based therapies for dominantly inherited retinopathies.

Authors:  G J Farrar; S Millington-Ward; N Chadderton; P Humphries; P F Kenna
Journal:  Gene Ther       Date:  2011-11-17       Impact factor: 5.250

5.  Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning.

Authors:  Jaap Jan Boelens; Mieke Aldenhoven; Duncan Purtill; Annalisa Ruggeri; Todd Defor; Robert Wynn; Ed Wraith; Marina Cavazzana-Calvo; Attilio Rovelli; Alain Fischer; Jakub Tolar; Vinod K Prasad; Maria Escolar; Eliane Gluckman; Anne O'Meara; Paul J Orchard; Paul Veys; Mary Eapen; Joanne Kurtzberg; Vanderson Rocha
Journal:  Blood       Date:  2013-03-14       Impact factor: 22.113

6.  Effect of gene therapy on visual function in Leber's congenital amaurosis.

Authors:  James W B Bainbridge; Alexander J Smith; Susie S Barker; Scott Robbie; Robert Henderson; Kamaljit Balaggan; Ananth Viswanathan; Graham E Holder; Andrew Stockman; Nick Tyler; Simon Petersen-Jones; Shomi S Bhattacharya; Adrian J Thrasher; Fred W Fitzke; Barrie J Carter; Gary S Rubin; Anthony T Moore; Robin R Ali
Journal:  N Engl J Med       Date:  2008-04-27       Impact factor: 91.245

7.  T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years.

Authors:  R M Blaese; K W Culver; A D Miller; C S Carter; T Fleisher; M Clerici; G Shearer; L Chang; Y Chiang; P Tolstoshev; J J Greenblatt; S A Rosenberg; H Klein; M Berger; C A Mullen; W J Ramsey; L Muul; R A Morgan; W F Anderson
Journal:  Science       Date:  1995-10-20       Impact factor: 47.728

8.  Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.

Authors:  Z Eshhar; T Waks; G Gross; D G Schindler
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-15       Impact factor: 11.205

9.  Hormone replacement therapy in Leber's hereditary optic neuropathy: Accelerated visual recovery in vivo.

Authors:  Michele Fantini; Samuel Asanad; Rustum Karanjia; Alfredo Sadun
Journal:  J Curr Ophthalmol       Date:  2018-11-03

10.  Search-and-replace genome editing without double-strand breaks or donor DNA.

Authors:  Andrew V Anzalone; Peyton B Randolph; Jessie R Davis; Alexander A Sousa; Luke W Koblan; Jonathan M Levy; Peter J Chen; Christopher Wilson; Gregory A Newby; Aditya Raguram; David R Liu
Journal:  Nature       Date:  2019-10-21       Impact factor: 69.504

View more
  3 in total

1.  CRISPR correction of the Finnish ornithine delta-aminotransferase mutation restores metabolic homeostasis in iPSC from patients with gyrate atrophy.

Authors:  Rocio Maldonado; Sami Jalil; Timo Keskinen; Anni I Nieminen; Mervi E Hyvönen; Risto Lapatto; Kirmo Wartiovaara
Journal:  Mol Genet Metab Rep       Date:  2022-04-01

2.  A clinical, histopathological, and molecular study of two cases of VEXAS syndrome without a definitive myeloid neoplasm.

Authors:  Peng Li; Shobi Venkatachalam; Daniela Ospina Cordona; Lorena Wilson; Tibor Kovacsovics; Karen A Moser; Rodney R Miles; David B Beck; Tracy George; Srinivas K Tantravahi
Journal:  Blood Adv       Date:  2022-01-25

Review 3.  Gene Therapy and Hemophilia: Where Do We Go from Here?

Authors:  Nancy S Bolous; Nidhi Bhatt; Nickhill Bhakta; Ellis J Neufeld; Andrew M Davidoff; Ulrike M Reiss
Journal:  J Blood Med       Date:  2022-10-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.